Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision | ||
group_2_presentation_3_-_cancer [2020/03/26 20:29] gandhr11 [CRISPR-Cas9] |
group_2_presentation_3_-_cancer [2020/03/26 22:36] (current) gandhr11 [What did the study do?] |
||
---|---|---|---|
Line 109: | Line 109: | ||
{{youtube>2pp17E4E-O8?medium | center}} | {{youtube>2pp17E4E-O8?medium | center}} | ||
+ | |||
==== What did the study do? ==== | ==== What did the study do? ==== | ||
+ | The researchers began by collecting the patients T-cells from their blood. Following that, they used the CRISPR-Cas9 system to edit three genes (TRAC, TRBC, PD-1). TRAC and TRBC are the T-cell's natural receptors and they were removed and reprogrammed to express a synthetic T-cell receptor which would seek out and destroy tumors. The research article mentions that the transgenic TCR ( T-cell) Receptor has been shown to mis pair and/or compete for expression with the a and b chains of the endogenous/original TCR. Mispairing of the therapeutic TCR a and b chains with endogenous a and b chains reduces therapeutic TCR cell surface expression and potentially generates self-reactive TCRs. The third edit removed PD-1, a natural checkpoint that sometimes blocks T cells from doing their job. Once the three genes are knocked out, a fourth genetic modification was accomplished using a lentivirus to insert the cancer-specific synthetic T cell receptor, which tells the edited T cells to target an antigen called NY-ESO-1. Previously published data show these cells typically survive for less than a week, but this new analysis shows the edited cells used in this study persisted, with the longest follow up at nine months. | ||
+ | <WRAP center round box 50%> | ||
+ | {{ :cancerstudy.png?direct |}} | ||
+ | **Figure 4: Retrieved from the study referenced at the start of the section** | ||
+ | </WRAP> | ||
| | ||
====== Conclusion ====== | ====== Conclusion ====== |